Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners
Will Fund Clinical Trials of Company’s First iPSC-derived Autologous Dopamine Neuron Replacement for Parkinson’s Disease FOR IMMEDIATE RELEASE CONTACT:Angelyn Lowemedia@aspenneuro.com SAN DIEGO, Calif., May 9, 2022 — Aspen Neuroscience, Inc., a private biotechnology company developing autologous cell therapies, including the first iPSC-derived autologous neuron replacement treatment for Parkinson’s disease (PD), today announced the close of … Read more
Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.
